Which Type of Meta-Analysis Do You Need? Pairwise, Network, IPD, Diagnostic Accuracy, Proportion or Dose-Response: A Decision Tree
The type of meta-analysis is fixed by the research question and the data structure, not by software preference. Choosing the wrong model produces a pooled estimate that cannot answer the question asked.

- Types covered
- Six
- Decides the type
- Research question and data structure
- Default
- Pairwise, when no other branch applies
- Reporting
- PRISMA 2020 plus the matching extension
Quick answer
- Diagnostic accuracy, single-group frequency, exposure gradient and multiple treatments each need their own model.
- Check data feasibility against a scoping search before registering the protocol.
- Report with PRISMA 2020 and the matching extension, and grade certainty with GRADE.
01Six types of meta-analysis at a glance
The types of meta-analysis differ in the question they answer, the data they need and the PRISMA extension that governs reporting (Table 1). In every case the meta-analysis sits inside a systematic review, and the model must match the research question.
| Type | Question answered | Data input | Typical model | Reporting standard |
|---|---|---|---|---|
| Pairwise | Is A better than B? | Aggregate effect sizes (RR, OR, MD, SMD) | Common-effect or random-effects model (REML) | PRISMA 2020 [1] |
| Network | Which of three or more interventions works best? | Direct and indirect comparisons | Frequentist or Bayesian NMA, with ranking | PRISMA-NMA [2] |
| IPD | Does the effect vary by participant characteristics? | Participant-level records | One-stage or two-stage models | PRISMA-IPD [3] |
| Diagnostic test accuracy | How accurate is the test? | 2×2 tables per study | Bivariate model or HSROC | PRISMA-DTA [4] |
| Proportion | How common is the outcome? | Events and sample size, single group | GLMM (logit link) or transformed proportions | PRISMA 2020; MOOSE for observational studies [5] |
| Dose-response | Does risk change with exposure level? | Category-specific estimates with doses | Greenland–Longnecker; restricted cubic splines | PRISMA 2020; MOOSE for observational studies [5] |
02Decision tree: how to choose the right type of meta-analysis
Work through the questions in order (Table 2). The first “yes” gives the design; a pairwise meta-analysis is the default when every answer is “no”.
| Step | Question | If yes | If no |
|---|---|---|---|
| Q1 | Is the outcome a test’s accuracy against a reference standard? | Diagnostic test accuracy meta-analysis | Go to Q2 |
| Q2 | Is a single-group frequency (prevalence, incidence, complication rate) pooled without a comparator? | Proportion meta-analysis | Go to Q3 |
| Q3 | Is exposure reported at several quantitative levels (a reference plus at least two others), with interest in the trend? | Dose-response meta-analysis | Go to Q4 |
| Q4 | Are three or more interventions compared within a connected evidence network? | Network meta-analysis (verify transitivity) | Go to Q5 |
| Q5 | Is participant-level data obtainable, or are subgroup, time-to-event or covariate interactions central? | IPD meta-analysis | Pairwise meta-analysis |
IPD is a data source as much as a design: an IPD network meta-analysis or IPD diagnostic review is possible when raw data exist for several comparisons or tests [6].
03Model-specific technical considerations
Pairwise meta-analysis
Select the effect measure before extraction. Risk ratios and odds ratios suit binary outcomes, with risk differences for absolute effects; mean differences suit outcomes on the same scale, and standardised mean differences (Hedges’ g) pool different instruments measuring one construct. Pool time-to-event outcomes as hazard ratios using the log HR and its standard error, not as dichotomised counts at an arbitrary time point.
Quantify heterogeneity with τ² and I², and report a prediction interval, because I² is the proportion of variability due to between-study differences, not its magnitude [9]. In a random-effects model, prefer REML or Paule–Mandel estimators over DerSimonian–Laird [7], and consider the Hartung–Knapp adjustment for the confidence interval, especially when studies are few [8].
Network meta-analysis
Assess transitivity by comparing the distribution of effect modifiers across comparisons, then test consistency between direct and indirect evidence with node-splitting or design-by-treatment interaction models [10]. Present the network geometry and report rankings (SUCRA or P-scores) with their uncertainty, alongside effect estimates rather than in place of them [2].
Individual participant data (IPD)
A one-stage model analyses all participants at once, stratified by study; a two-stage approach estimates effects within each study before pooling [6]. Separate within-study treatment–covariate interactions from across-study associations to avoid ecological bias [11]. Report the data obtained, data checking and studies without IPD, as PRISMA-IPD requires [3].
Diagnostic test accuracy
Sensitivity and specificity are correlated through threshold variation, so pooling them separately is incorrect. The bivariate model estimates both jointly, with their correlation, and gives a summary point and confidence region [12]. The HSROC model [13] is equivalent without covariates and is used when interest lies in the summary curve across thresholds.
Proportion meta-analysis
Untransformed proportions near 0 or 1 have unstable variances. The Freeman–Tukey double arcsine transformation has been advocated for prevalence [14], but its back-transformation can give seriously misleading results, and generalised linear mixed models with a logit link are now preferred [15].
Dose-response meta-analysis
Category-specific estimates within a study share a reference group and are correlated. The Greenland–Longnecker method estimates this covariance from reported cases and totals [16]; restricted cubic splines then test non-linearity [17]. Assign doses using category midpoints and document rules for open-ended categories during data extraction.
04Data requirements before choosing a meta-analysis method
Confirm feasibility during protocol development, before registration. Check each type’s minimum data (Table 3) against a scoping search and pilot data extraction.
| Type | Minimum data per study | Feasibility check |
|---|---|---|
| Pairwise | Effect estimate with SE, or 2×2 / mean (SD) per arm | At least two comparable studies per outcome |
| Network | Arm-level or contrast-level data for every comparison | Connected network; effect modifiers reported |
| IPD | Participant records with outcome, treatment and covariates | Data-sharing agreements and expected retrieval rate |
| Diagnostic test accuracy | TP, FP, FN, TN at a stated threshold | Common reference standard across studies |
| Proportion | Number of events and denominator | Comparable case definitions and populations |
| Dose-response | Cases and person-time or totals per exposure category | Reference plus at least two exposure levels with dose values; more levels to test non-linearity |
05Small-study effects and certainty of evidence by meta-analysis type
Funnel plots and Egger’s test assume a comparative effect size and should not be used with fewer than ten studies [18]. For diagnostic test accuracy reviews, use Deeks’ funnel plot, which plots the log diagnostic odds ratio against 1/√(effective sample size) [19]. For proportion meta-analysis, funnel asymmetry is hard to interpret because there is no null effect against which small studies would be selectively published [20].
Grade the certainty of evidence for each main pooled estimate with GRADE, using the network-specific approach for NMA estimates [21] and the GRADE approach for diagnostic tests in accuracy reviews [22]. PRISMA 2020 asks you to report how certainty was assessed [1].
06Common mistakes when choosing a meta-analysis method
- Running a network meta-analysis on a disconnected network, or without assessing transitivity.
- Pooling sensitivity and specificity in two univariate models instead of a bivariate model.
- Choosing a random-effects model only because I² exceeds 50%, rather than on the expected heterogeneity of the evidence synthesis.
- Treating dose categories as independent studies in a dose-response meta-analysis.
- Omitting GRADE certainty of evidence for the primary pooled estimate.
For reporting detail, see our guide to meta-analysis reporting standards, and for reading the output, how to read a forest plot.
Questions
Can I run a network meta-analysis if some comparisons have no head-to-head trials?
Yes, provided all interventions are connected through at least one common comparator and transitivity holds. Disconnected treatments cannot be ranked against the rest of the network.
Why can’t sensitivity and specificity be pooled separately?
They are negatively correlated through differences in positivity thresholds. Separate pooling ignores this correlation; the bivariate or HSROC model accounts for it.
Is a high I² enough to justify a random-effects model?
No. Choose the model on whether studies are expected to estimate different true effects, which is usual in clinical evidence synthesis, and report τ² and a prediction interval as well as I².
References
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
- Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777-784. https://doi.org/10.7326/M14-2385
- Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657-1665. https://doi.org/10.1001/jama.2015.3656
- McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388-396. https://doi.org/10.1001/jama.2017.19163
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting (MOOSE). JAMA. 2000;283(15):2008-2012. https://doi.org/10.1001/jama.283.15.2008
- Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. https://doi.org/10.1136/bmj.c221
- Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55-79. https://doi.org/10.1002/jrsm.1164
- IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. https://doi.org/10.1186/1471-2288-14-25
- Borenstein M, Higgins JPT, Hedges LV, Rothstein HR. Basics of meta-analysis: I² is not an absolute measure of heterogeneity. Res Synth Methods. 2017;8(1):5-18. https://doi.org/10.1002/jrsm.1230
- Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7-8):932-944. https://doi.org/10.1002/sim.3767
- Fisher DJ, Carpenter JR, Morris TP, et al. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? BMJ. 2017;356:j573. https://doi.org/10.1136/bmj.j573
- Reitsma JB, Glas AS, Rutjes AWS, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982-990. https://doi.org/10.1016/j.jclinepi.2005.02.022
- Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865-2884. https://doi.org/10.1002/sim.942
- Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974-978. https://doi.org/10.1136/jech-2013-203104
- Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rücker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019;10(3):476-483. https://doi.org/10.1002/jrsm.1348
- Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135(11):1301-1309. https://doi.org/10.1093/oxfordjournals.aje.a116237
- Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012;175(1):66-73. https://doi.org/10.1093/aje/kwr265
- Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. https://doi.org/10.1136/bmj.d4002
- Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):882-893. https://doi.org/10.1016/j.jclinepi.2005.01.016
- Hunter JP, Saratzis A, Sutton AJ, et al. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol. 2014;67(8):897-903. https://doi.org/10.1016/j.jclinepi.2014.03.003
- Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630. https://doi.org/10.1136/bmj.g5630
- Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-1110. https://doi.org/10.1136/bmj.39500.677199.AE
Update log
- Published by Pubrica
How to cite this article
Dr. Charlie. (2026, November 2). Which Type of Meta-Analysis Do You Need? Pairwise, Network, IPD, Diagnostic Accuracy, Proportion or Dose-Response: A Decision Tree. Pubrica. https://pubrica.com/academy/meta-analysis/meta-analysis-type-decision-tree/
This article is general information for researchers, not legal, regulatory or funding advice. Check the current requirements of your journal, funder, ethics committee or regulator before you act on it.